Setting new standards in information exchange for the pharmaceutical and biotech industry
IO360° Speaker Dr. Carl June Launches New T-Cell Company, Tmunity Therapeutics
January 26, 2016
Congratulations to Immuno-Oncology 360° speaker Dr. Carl June, Director of the Translational Research Program at the University of Pennsylvania who recently co-founded Tmunity Therapeutics, an organization that is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications.
“The creation of Tmunity is the culmination of a more than decade-long commitment by Penn and our founding team to link basic and translational research with clinical trial investigation, and will ensure that we remain at the leading edge in advancing cell therapies for multiple diseases,” said Carl H. June, MD, co-founder and chief scientific advisor of Tmunity Therapeutics.
Dr. Carl June will be chairing and delivering a talk on CAR-T data for hematologic malignancies at the 2nd Annual Immuno-Oncology 360° conference taking place February 2-3, 2016 in NYC.
PHILADELPHIA, Jan. 12, 2016 /PRNewswire-USNewswire/ — Tmunity Therapeutics today announced that it is raising $10 Million in equity financing from Penn Medicine, the academic medical center of the University of Pennsylvania (Penn), and Lilly Asia Ventures, a premier venture capital firm focused on making investments in the life sciences sector. The financing will represent the first capital investment for Penn Medicine in a company co-founded by Penn faculty and researchers. The proceeds of the financing will be used to develop novel products to unleash the immunological potential of T cells to treat a wide range of diseases. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo. The company is also developing proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. These will rapidly advance toward the clinic personalized next-generation engineered T cell immunotherapies for cancer, infectious diseases and autoimmune disease.Read the full press release here: http://snip.ly/Fs7DTo learn more about the 2nd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/